1. A Study of Oral Etoposide, Infusional Cisplatin, and Infusional 5-Fluorouracil for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
- Author
-
Galen L. Wampler, Jacob J. Lokich, John G. Fryer, James D. Ahlgren, D Alt, Rosenthal Cj, and H D Brereton
- Subjects
Adult ,Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,medicine.medical_treatment ,Administration, Oral ,Carcinoma, Non-Small-Cell Lung ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Medicine ,Infusions, Intravenous ,Lung cancer ,Etoposide ,Aged ,Cisplatin ,Chemotherapy ,business.industry ,Remission Induction ,Respiratory disease ,Middle Aged ,medicine.disease ,Combined Modality Therapy ,Survival Analysis ,Confidence interval ,Regimen ,Fluorouracil ,Drug Evaluation ,Female ,business ,medicine.drug - Abstract
A combination of oral etoposide, infusional cisplatin (24-hr) and infusional 5-fluorouracil (5-day) was used to treat 87 patients with non-small-cell lung cancer in a Phase II trial. Twenty-six patients were Stage IIIB, and 61 patients were Stage IV (new international classification). The regimen was well tolerated, with 49% grade 3 or 4 toxicities of all types. Response rates, partial and complete, were 40%, (95% confidence interval: 30%, 51%) for Stage IV patients and 20% (95% confidence interval: 10%, 32%), in Stage IIIB. An additional 68% of patients in Stage IIIB and 45% of patients in Stage IV achieved stable disease and had a median survival of 8.8 months, similar to that of patients in partial remission. Median survival was 5.6 months (95% confidence interval: 4.4 months, 10.8 months) for Stage IV patients and 11.0 months (95% confidence interval: 8.8 months, 12.4 months), for Stage IIIB. Of interest was the finding of a higher response rate in patients with a shorter duration of symptoms (less than 6 months versus greater than 6 months).
- Published
- 1992
- Full Text
- View/download PDF